Blog

The Alliance’s blog offers a personal, inside look at our activities and perspectives on a range of timely issues. We encourage your feedback.

FDA Under Fire

Author: Guest Contributor

Date: November 14th, 2011

Last month, the FDA published a long awaited report on biomedical innovation, their only course of defense in the recent onslaught against the agency. Historically, the FDA has played a significant role in the protection of our health, assuming sole responsibility for the approval of medical products, but it appears that congressional confidence in the agency is waning.


FDA Needs More Funding to Fulfill Its Mission

Author: Cynthia Bens

Date: March 18th, 2008

On February 4, 2008, the Bush administration released its proposed budget recommendations for funding all federal agencies in fiscal year 2009. Under this proposal, the U.S. Food and Drug Administration would receive a 2.9% overall increase in funding this year.


ACT-AD Coalition Holds Eighth Annual Meeting

Author: Noel Lloyd

Date: September 18th, 2015

On September 16 the ACT-AD (Accelerate Cure/Treatments for Alzheimer's Disease) Coalition hosted its Eighth Annual FDA/Alzheimer’s Disease Allies Meeting in North Bethesda, Md.


Alliance President and CEO Sue Peschin on Being at the White House Conference on Aging

Author: Noel Lloyd

Date: July 14th, 2015

Yesterday, the White House Conference on Aging was held in Washington, D.C. Our President and CEO Sue Peschin was among the individuals in attendance. 


Expert Robert Fielding on the Latest in Sarcopenia Research

Author: Noel Lloyd

Date: June 30th, 2015

To help you learn more about what's been going on in the sarcopenia research space, we are linking you to an interview with Roger A. Fielding, Ph.D.


The 21st Century Cures Act: A Critical Bill to Improve the Future of Medical Research in America

Author: Noel Lloyd

Date: June 12th, 2015

The 21st Century Cures Act represents a positive change in how American biomedical research will be conducted and streamlines the processes intended to deliver new medical cures and treatment to patients.


Alliance Offers Comment on FDA Testosterone Prescription Labeling Communication

Author: Noel Lloyd

Date: March 4th, 2015

Type: Blog Post

We wanted to share our reaction to communication from the U.S. Food and Drug Administration regarding updates to the labeling of prescription testosterone products.


Matching the Needs of Patients with Those of Our Federal Health Agencies

Author: Cynthia Bens

Date: February 12th, 2015

On Tuesday, the Alliance for Aging Research responded to the U.S. House Energy and Commerce Committee 21st Century Cures Initiative and its recently released discussion draft.


Don’t Just Act Out, Act to Increase Representation in Clinical Trials

Author: Cynthia Bens

Date: August 29th, 2014

Vice President of Public Policy Cynthia Bens talks about clinical trials.


Turning a Blind Eye on Patients

Author: Cynthia Bens

Date: May 22nd, 2014

Type: Blog

Alliance Vice President of Public Policy Cynthia Bens discusses AMD and older adults. 


Are we there yet?

Author: Cynthia Bens

Date: January 6th, 2012

Many of you may still have this phrase ringing in your ears if you traveled with children for any length of time this past holiday season. Representatives from the ACT-AD Coalition, chaired by the Alliance for Aging Research, heard these same words almost two years ago, not uttered from the mouths of babes, but rather by prominent officials at the Food and Drug Administration (FDA) in a conversation regarding evidence to support the use of biomarkers for Alzheimer’s disease in clinical trials for “disease-modifying” therapies.


A "Pro-Cures" FDA

Author: Dan Perry

Date: January 28th, 2009

One week into the Obama Administration and the choice of a new Commissioner of the Food and Drug Administration may be only days away. This is a critical moment for anyone who will face a life-threatening or life-shortening disease or disability. Aging Baby Boomers take note: in time, if not right now, the FDA choice will affect you directly and personally.


Cynthia Bens Comments from MDUFA and PDUFA Meetings

Author: Noel Lloyd

Date: July 16th, 2015

Alliance Vice President of Public Policy Cynthia Bens took part in two important meetings at the U.S. Food and Drug Administration this week.


Alliance Applauds Passage of 21st Century Cures Act in House

Author: Noel Lloyd

Date: July 10th, 2015

The Alliance for Aging Research has issued the following statement on the passage of the 21st Century Cures Act, or H.R. 6, today in the U.S. House of Representatives.


Webinar: Targets for the Next Generation of Alzheimer’s Disease Treatment

Author: Noel Lloyd

Date: May 11th, 2015

On April 27 the Alliance's ACT-AD Coalition held a webinar on the future of research, therapeutic development, and treatment of Alzheimer’s disease.


Infographic on Pain Incidence and Management

Author: Noel Lloyd

Date: March 10th, 2015

Today we released a survey of 1,600 Americans ages 18 and over that reveals insights on pain and OTC pain medications. This infographic offers a summary of the results.


Let This Be a Lesson for Change

Author: Susan Peschin, MHS

Date: August 26th, 2014

Alliance President and CEO Susan Peschin, MHS, on mental health in older adults


PDUFA V Can Help Patients and the FDA

Author: Dan Perry

Date: June 30th, 2011

On June 26, 2011 I was interviewed by BioCentury This Week to share the Alliance for Aging Research’s impressions on the fifth reauthorization of the Food and Drug Administration’s Prescription Drug User Fee program. Thanks to Congress, we and other active patient groups were able to lend an early voice in helping to shape how user fees might be used to help speed the delivery of better treatments and cures to patient in need of relief from Alzheimer’s, Cancer, Parkinson’s and many more diseases.

 


A December Update on PDUFA and MDUFA

Author: Noel Lloyd

Date: December 22nd, 2015

A December update on PDUFA and MDUFA


The President’s Budget: Read the Numbers, Not the Headlines

Author: Ryne Carney

Date: February 18th, 2016

The Obama administration’s FY 2017 vision for the federal government does not include continuing increases for America’s biomedical research community.


HROTW: Infographic on What Americans Feel about Pain

Author: Noel Lloyd

Date: September 23rd, 2015

For our Health Resource of the Week, we share this infographic to make you aware about what Americans feel about pain and what they do to treat it.


Alliance Offers Comments on FDA OTC Monograph User Fees

Author: Noel Lloyd

Date: June 15th, 2016

Last Friday, on June 10, Vice President of Public Policy Cynthia Bens presented comments on behalf of the Alliance at a U.S. Food and Drug Administration public meeting focused on OTC monograph user fees. 


Alliance’s Bens Presents at August PDUFA VI Public Meeting

Author: Noel Lloyd

Date: August 18th, 2016

The Alliance’s Vice President of Public Policy Cynthia Bens was invited by the U.S. Food and Drug Administration (FDA) to speak on two panels at an August 15 public meeting focused on the sixth reauthorization of the Prescription Drug User Fee Act (PDUFA).


Alliance Comments on the FDA's Commitment Letter for PDUFA VI

Author: Noel Lloyd

Date: August 30th, 2016

In response to a call from the U.S. Food and Drug Administration (FDA) for feedback on its proposed Commitment Letter for the sixth reauthorization of the Prescription Drug User Fee Act (PDUFA), the Alliance for Aging Research submitted comments to the FDA for consideration.


Congress and the Omnibus Miracle

Author: Susan Peschin, MHS

Date: December 17th, 2015

Congress gave Americans a holiday miracle this week and reached a deal on a $1.1 trillion omnibus spending bill for FY 2016, increasing funding for NIH, NIA, and FDA.


HROTW: Learn More about Vaccinations

Author: Noel Lloyd

Date: August 27th, 2015

Our Health Resource of the Week focuses on some of the ways you can learn about why vaccinations keep us safe, no matter what our age.  


An Update on 21st Century Cures

Author: Noel Lloyd

Date: October 31st, 2016

We provide an update on the 21st Century Cures Act, an important piece of legislation that the Alliance has been advocating for.


ACT-AD Will Host Ninth Annual Meeting

Author: Breanna Bishop

Date: October 31st, 2016

The ACT-AD Coalition will host its Ninth Annual FDA/Alzheimer's Disease Allies Meeting on November 16, 2016. 


ACT-AD Coalition Holds Ninth Annual Meeting

Author: Breanna Bishop

Date: November 22nd, 2016

On November 16, the ACT-AD (Accelerate Cure/Treatments for Alzheimer’s Disease) Coalition hosted its Ninth Annual FDA/Alzheimer’s Disease Allies Meeting in North Bethesda, Md., to discuss the current state of Alzheimer’s disease treatment development.


Alliance Releases Statement on Passage of 21st Century Cures

Author: Noel Lloyd

Date: December 7th, 2016

The Senate today approved landmark legislation overhauling the development of medical treatments and cures for patients, which represents the culmination of a multi-year, bipartisan initiative in Congress. Here is a statement from Alliance President and CEO Sue Peschin.


AIM Coalition Held Second Annual Meeting

Author: Breanna Bishop

Date: December 15th, 2016

On December 2, the Aging in Motion (AIM) Coalition hosted its second annual meeting in Bethesda, Md., to discuss developments and advances in clinical research and treatment of sarcopenia.


Alliance Issues Statement on the Protect Medical Innovation Act of 2017

Author: Noel Lloyd

Date: January 3rd, 2017

The Alliance has issued the following statement from President and CEO Susan Peschin, MHS, regarding the introduction of the Protect Medical Innovation Act of 2017


Tomorrow Is the March for Science

Author: Noel Lloyd

Date: April 21st, 2017

This Saturday, April 22, thousands of people will gather in the shadow of the Washington Monument to march for not just a cause, but in support of one of humanity’s most important endeavors: science.


Five Questions (and Answers) about the FDA Reauthorization Act of 2017

Author: Noel Lloyd

Date: July 12th, 2017

Right now, the U.S. Congress is considering the FDA Reauthorization Act of 2017 , legislation that will reauthorize the pharmaceutical, medical device, generic drug, and biosimilar user fee agreements. The five-year deal is one of the most important health care bills Congress will vote on this year.

Living Longer & Loving It

Sign up for our electronic newsletter Living Longer & Loving It